Floatz logo

Liposomal Cytarabine-Daunorubicin Cpx-351

Acute Myeloid Leukemia

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.unclassifiedPhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Liposomal Cytarabine-Daunorubicin Cpx-351 is also rated in:

acute erythroid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
acute megakaryoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →